Filing Flows › Harmony Biosciences Holdings (HRMY) › Gross margin
Harmony Biosciences Holdings (HRMY) gross margin by quarter
Harmony Biosciences Holdings' gross margin was 70.0% in Q3 2026 (third quarter 2026), -5.8 pts from Q2 2026. Over the last 7 quarters it ranged from 70.0% (Q3 2026) to 82.7% (Q1 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 70.0% | -5.8 pts | -5.1 pts |
| Q2 2026 | 75.8% | -3.5 pts | -5.2 pts |
| Q1 2026 | 79.3% | +7.5 pts | -3.3 pts |
| Q4 2025 | 71.9% | -3.2 pts | — |
| Q3 2025 | 75.1% | -5.9 pts | — |
| Q2 2025 | 81.0% | -1.7 pts | — |
| Q1 2025 | 82.7% | — | — |
Q3 2026 at a glance
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Harmony Biosciences Holdings' gross margin?
Harmony Biosciences Holdings' gross margin was 70.0% in Q3 2026 (third quarter 2026), -5.8 pts from Q2 2026.
How has Harmony Biosciences Holdings' gross margin changed?
Over the last 7 quarters it ranged from 70.0% (Q3 2026) to 82.7% (Q1 2025).
Q3 2026 results → · How Harmony Biosciences Holdings makes money →